The inaugural CARE Winter Hematology Update took place on February 23rd, 2018 at the Shangri-La Hotel in Toronto, Ontario. CARE was pleased to welcome an excellent Faculty of Canadian key opinion leaders (KOLs) with expertise in a diverse set of hematological diseases. Members of the CARE Hematology Faculty presented updates from ASH 2017 and other key hematological news framed from a Canadian perspective.
This CARE meeting featured an exciting set of presentations covering the most impactful hematological topics, along with CARE Working Group Meetings - for smaller KOL groups to have focused, extended, discussions. The CARE Working Groups focused on managing CLL, MCL, ALL, MM, and WM in Canada.
CARE (Community Academic Research Education) believes in accessibility, competition, innovation with new treatments and the optimization of current therapy- with the goal of improving patient outcomes. CARE initiatives aim to educate Canadian health care professionals by providing updates on relevant medical news and developments, framed from a Canadian perspective.
CARE Hematology Faculty who have contributed to this report:
Dr. John Kuruvilla (Princess Margaret Cancer Centre)
Dr. Peter Anglin (Stronach Regional Cancer Centre)
Presenters and Authors:
Chronic Lymphocytic Leukemia (CLL) - Dr. Graeme Fraser (Juravinski Cancer Center)
Hodgkin’s Lymphoma (HL) - Dr. John Kuruvilla (Princess Margaret Hospital)
Multiple Myeloma (MM) - Dr. Christine Chen (Princess Margaret Hospital)
Myeloid Disorders and Transplant - Dr. Dennis Kim (Princess Margaret Hospital)
Non-Hodgkin’s Lymphoma (NHL) - Dr. Michael Crump (Princess Margaret Hospital)
Cell Therapy: CAR-T Focus - Dr. Ronan Foley (McMaster University)
Emerging Concepts in Cell Therapy - Dr. Rob Laister (Princess Margaret Hospital)
CARE Management Considerations Reports
Members of the CARE Ontario Hematology Faculty held Working Group meetings in conjunction with the CARE Winter Hematology Meeting - ASH Update on February 23rd in Toronto. During these meetings relevant news and data were considered from an Ontario perspective in the areas of multiple myeloma (MM), Waldenström’s macroglobulinemia (WM), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and acute lymphocytic leukemia (ALL).